We are Sorry, This Page doesn't Exist

Shares of Cassava Sciences Inc. tumbled 73.2% in trading on Friday after the company said its investigational Alzheimer's disease treatment failed a mid-.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Pea.....»»

Shares of Eli Lilly and Co. fell 4% in premarket trading on Monday after solanezumab, the experimental therapy it was testing in people with a form .....»»

Shares of Aimmune Therapeutics Inc. rose more than 12% in the extended session Friday after the Brisbane, Calif., company said the FDA has approved one of its drugs, Palforzia, for patients with peanut allergies. The o.....»»

DBV Tech shares jumped on Thursday after the firm announced positive topline results from its late-stage study in children with a peanut allergy......»»

Incyte Corp. shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal. Incyte said that a study seeking to pair itacitinib with corticosteroids to treat a form o.....»»

Shares of Sol-Gel Technologies Ltd. gained 154% in premarket trading on Monday after the Israeli drugmaker said its ac.....»»

Shares of Stealth BioTherapeutics tumbled 63% after it said a late-stage trial for its investigational treatment of primary mitochondrial myopathy, a muscular disease caused by genetic mutations, failed to meet the study's primary endpoint. .....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Aimmune Therapeutics Inc.'s stock has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is meeting a.....»»

Shares of Pfizer Inc. ticked up 1.2% in premarket trade Monday after the drugmaker said a Phase 4 study showed that an eczema treatment was well-tolerated in babies between 3 months and two years of age when used over a .....»»

BioCryst Pharmaceuticals shares were absolutely crushed in Tuesday’s session after the company announced late-stage results for its study in hereditary angioedema patients......»»

Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed to meet its primary endpoint of i.....»»

Shares of Celldex Therapeutics Inc. plummeted 40% in premarket trade Monday toward a record low, after the drug.....»»

Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses, that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals......»»

An experimental drug derived from peanuts protected some children and adolescents with life-threatening peanut allergies, according to a study, allowing the subjects to eat small amounts of peanuts without suffering a serious reaction......»»

Brainstorm Health Daily: November 19, 2018 Ha.....»»

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. read more.....»»

New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. read more.....»»

Organovo released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH).  read more.....»»